Advertisement

Pharmaceutical Chemistry Journal

, Volume 52, Issue 10, pp 863–864 | Cite as

Safe Use of Systemic Interferons for Multiple Sclerosis Treatment

  • I. I. SnegirevaEmail author
  • M. A. Darmostukova
  • A. S. Kazakov
  • V. K. Lepakhin
DRUGS
  • 30 Downloads

The safety of interferons was assessed by analyzing 499 spontaneous reports in the Russian database from 2015 to 2017. The results led to the conclusion that the safety profile of systemic interferon preparations that are widely used in medical practice to treat multiple sclerosis is defined by data in spontaneous reports for the development of adverse reactions to them or the ineffectiveness of using them.

Keywords

interferons spontaneous reports adverse reactions multiple sclerosis 

References

  1. 1.
    O. V. Bykova, A. N. Platonova, N. V. Gol’tsova, et al., Vopr. Sovrem. Pediatr., 8(6), 139 – 145 (2009).Google Scholar
  2. 2.
    F. Barkhof, C. Polman, E. Radue, et al., 21 st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Greece (2005), Abstr. 583.Google Scholar
  3. 3.
    H. Panitch, D. Goodin, G. Francis, et al., Neurology, 59, 1496 – 1506 (2002).CrossRefGoogle Scholar
  4. 4.
    D. S. Kasatkin and N. N. Spirin, Vestn. Novosib. Gos. Univ. Ser.: Biol. Klin. Med., 13(1), 30 – 37 (2015).Google Scholar
  5. 5.
    I. I. Snegireva, E. Yu. Pasternak, K. E. Zatolochina, et al., Bezop. Risk Farmakoter., 5(4), 161 – 169 (2017).Google Scholar
  6. 6.
    V. Yu. Lizhdvoi, T. P. Ospel’nikova, and S. V. Kotov, Al’manakh Klin. Med., 44(3), 318 – 323 (2016).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • I. I. Snegireva
    • 1
    Email author
  • M. A. Darmostukova
    • 1
  • A. S. Kazakov
    • 1
  • V. K. Lepakhin
    • 1
  1. 1.Scientific Center for Expert Evaluation of Medicinal ProductsMinistry of Health of the Russian FederationMoscowRussia

Personalised recommendations